Extended Pancreas Donor ProgramThe EXPAND Study: A Prospective Multicenter Trial Testing the Use of Pancreas Donors Older Than 50 Years by Proneth, Andrea et al.
OriginalClinicalScienceçGeneralExtended Pancreas Donor Program—The EXPAND
Study: A Prospective Multicenter Trial Testing the
Use of Pancreas Donors Older Than 50 Years
Andrea Proneth, MD,1 Andreas A. Schnitzbauer, MD,1,2 Peter Schenker, MD,3 Andreas Wunsch, MD,3
Falk Rauchfuss, MD,4 Helmut Arbogast, MD,5 Steffen Manekeller, MD,6 Silvio Nadalin, MD,7 Michael Heise, MD,8
Michael A. Ströhlein, MD,9 Bernhard Banas, MD,10 Peter Schemmer, MD,11 Thomas Becker, MD,12
Wolf O. Bechstein, MD,2 Andreas Pascher, MD,13 Richard Viebahn, MD,3 Edward K. Geissler, PhD,1
Hans J. Schlitt, MD,1 and Stefan A. Farkas, MD1Background.Pancreas transplantation is the only curative treatment option for patients with juvenile diabetes. Organ shortage
and restrictive allocation criteria are the main reasons for increasing waitlists, leading to severe morbidity and mortality. We designed a
study to increase the donor pool with extended donor criteria (EDC) organs (donor age, 50-60 years; body mass index, 30-34 kg/m2).
Methods. Utilization of EDC organs required the implementation of a new allocation system within Eurotransplant. The study was a
prospective, multicenter, 2-armed trial. The primary endpoint was pancreas function after 3 months. Rejection episodes, kidney func-
tion, and waitlist time were secondary endpoints. Patients receiving an EDC organ were study group patients; recipients of stan-
dard organs were control group patients. Follow-up was 1 year. Results. Seventy-nine patients were included in 12 German
centers, 18 received EDC organs and 61 received standard organs. Recipient demographics were similar. Mean EDC donor
age was 51.4 ± 5 years versus 31.7 ± 12 in the control group. Insulin-free graft survival was 83.3% for EDC and 67.2% for stan-
dard organs (P = 0.245) after 3 months. One-year pancreas survival was 83.3% and 83.5% in the EDC versus standard group.
One-year kidney allograft survival was approximately 94% in both groups. Rejection episodes andmorbidity were similar.Conclusions.
The Extended Pancreas Donor Program (EXPAND) shows in a prospective trial that selected EDC organs of donors older than
50 years can be used with outcomes similar to standard-criteria organs, therefore showing potential to reduce organ shortage
and waiting times. This study substantiates the full implementation of EDC organs in a pancreas allocation system.
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© 2018 Wolters Kluwer Proneth et al 1331Patients with type 1 (juvenile) diabetes mellitus experi-ence long-term complications, mostly related to vas-
cular disease. Associated nephropathy can lead to dialysis
with its own major risk factors for cardiovascular disease
and poor life quality. Simultaneous pancreas kidney (SPK)
transplantation or pancreas transplantation after kidney (PAK)
are the only curative treatment options for patients with type
1 diabetes and impaired kidney function.1,2 Patients on the
waitlist have only a 58% 4-year survival rate compared with
90% after SPK.3 With this clear potential to restore life qual-
ity and length,4-6 it is crucial to perform transplantation in
these patients as soon as possible.
Unfortunately, waitlists are continually increasing, leading
to overall progressive patient deterioration. In 2000, there
were 195 people on the waitlist for pancreas transplantation
in the Eurotransplant (ET) region, with a total of 301 transplan-
tations performed; in 2015, thewaitlist increased to 412 patients,
but only 192 transplantations were performed. Therefore,
waitlist times nearly doubled within 15 years and are now
close to 2 years (ET data), predictably worsening outcomes
and morbidity for these patients. When researching the rea-
sons, we found that—with constantly increasing mean donor
age—large numbers of pancreas allografts potentially avail-
able for transplantation were being excluded due to strict
ET Pancreas Allocation System criteria. These criteria excluded
donors older than 50 years and those with a body mass index
(BMI) greater than 30 kg/m2 (ET manual version, May 26,
2009). Because the average age of a postmortal organ donor
in the ETarea is 58 years, and almost 50%ofGerman donors
are older than 55 years, donor selection by age is amajor donor
organ shortage factor. Compounding the problem in Germany,
“non–heart-beating” donors are not legally allowed. Thus,
extension of the donor pool is only possible by using organs
from donors with higher age or BMI.
Currently available retrospective data from centers out-
side the ET area suggest a similar outcome after transplan-
tation using extended donor criteria (EDC) organs,7,8 but no
prospective-controlled trials have tested this presumption.
Therefore, the aim of our multicenter trial was to investigate
the hypothesis that organs from donors aged 50 to 60 years
or with a BMI greater than 30 kg/m2, using local allocation
with shorter ischemic times, can be transplanted with sim-
ilar results when compared with the standard criteria organs.
This trial was performed at multiple clinical sites in Germany
over a 4-year period.
MATERIALS AND METHODS
Study Design
The Extended Pancreas Donor Program (EXPAND) was
conducted as a prospective, multicenter, single-blinded,
nonrandomized, 2-armed trial comparing outcomes after
SPK, pancreas transplantation alone (PTA), or PAK trans-
plantation of organs with standard donor criteria to ex-
tended criteria donors. Extended criteria donors were
defined as having a BMI of 30 to 34 kg/m2 or between ages
50 and 60 years. Randomization was not possible because
group assignment depended on the type of organ a patient
was allotted by the ET allocation system. Patients who re-
ceived a standard criteria organ were included in the control
group, and patients receiving an EDC organ were included
into the study group. Patients were blinded to the type of organCopyright © 2018 Wolters Kluwer Hthey received. The enrollment phase was 3 years with a 1-year
follow-up period; the first patient was included in July 2011.
The last patient visit was conducted in April 2015.
The primary endpoint was insulin-free graft survival (graft
in situ with detectable c-peptide and no requirement of insu-
lin application to the recipient) of the EDC pancreas allograft
at 3 months posttransplantation. Insulin weaning policies
were center-specific during the first month after transplanta-
tion. Overall survival (OS), pancreas graft survival (graft in
situ with detectable c-peptide), kidney graft survival, as well
as morbidity, and hospitalization data were assessed as sec-
ondary endpoints. Secondary endpoints additionally included
biopsy-proven acute rejections and time on the waitlist. All
patients on the waitlist for primary SPK, PTA, or PAK were
trial eligible with inclusion criteria including being 18 years
or older and a negative crossmatch. The main exclusion
criteria were malignant diseases within the past 5 years before
transplantation (excluding squamous cell carcinoma and basal
cell carcinoma of the skin), as well as patients listed for pan-
creas retransplantation and women of childbearing potential
not willing to take contraceptives.
Patients received a standardized immunosuppressive treat-
ment consisting of induction therapy (depleting or nondeplet-
ing antibodies), steroids, tacrolimus, and mycophenolic acid/
mycophenolate mofetil. Early withdrawal of steroid-specific
immunosuppression use.
Allocation
The allocation algorithm for potential deceased pancreas
donors is regulated and defined in the ET handbook, Pancreas
Allocation Algorithms. Before the EXPAND Study, the cutoff
criteria for standard criteria donors were set to an age younger
than 50 years or a BMI less than 30 kg/m2. For these criteria,
allocation is performed according to HLA matching to the
recipient, urgency status of recipient, waitlist time, and so
on. Local distribution aspects are not incorporated into the
allocation system, often resulting in relatively long cold ische-
mic times.With the EXPAND study initiation, changes in the
allocation of EDC organs in Germany in this distribution sys-
tem were made (age, 50-60 years or BMI, 30-34 kg/m2) as
described in our study protocol.9
All deceased potential pancreas donors were screened for
eligibility using the revised allocation algorithm. Organs meet-
ing the standard criteria were allocated according to the previ-
ously existing system.Donorswith extended criteriawhowere
between 50 and 60 years of age or with a BMI of 30 to
34 kg/m2 were allocated according to the newly implemented
ET rescue allocation algorithm. These organs were allocated
only regionally to ensure a recommended cold ischemia time
(CIT) of less than 12 hours. The risk/benefit assessment of
accepting the allocated organs due to criteria, such as serum
amylase or lipase, donor time in the intensive care unit (ICU),
reanimation procedures, or use of vasoactive drugs, were made
at the discretion of the transplant surgeons in both groups, with
no distinct cutoff lines.
Study Oversight
The EXPAND study was an investigator-initiated trial
for which the University Hospital Regensburg was the sponsor
(trial registered at http://www.clinicaltrials.gov: NCT01384006).
Funding was provided by grants from Astellas (Munich,
Germany) and Novartis GmbH (Nürnberg, Germany); neitherealth, Inc. All rights reserved.
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pretation of the data. For accuracy, the sponsor monitored
all primary and secondary endpoint data on site by verifying
source data and case report form entries.
Statistical Plan and Analysis
The sample size was calculated by means of the primary
endpoint (ie, extended pancreas allograft survival rate after
3 months, assuming an expected rate of 80%10,11), whereas
the minimal accepted survival rate was set to 60%. The
60% limit is based on the maximally acceptable lower-organ
survival rate, as agreed upon during an EXPAND investiga-
tors meeting. The significance level of alpha (1-sided) was set
to 0.05 and beta was set to 0.20, this is in accordance with
the estimation of a 1-sided 90% confidence interval (CI) for
the survival rate after 3 months. A sample size of 34 patients
with an extended donor pancreas allograft achieves 80%
power to distinguish between the 2 proportions, 60% (p0)
and 80% (p1), using a 1-sided, binomial hypothesis test with
a target significance level of 0.05. Assuming a maximal drop-
out rate of 5%, 36 patients would be required for the primary
endpoint. The control group was planned to be at least equal
in size, consisting of patients with a standard donor pancreas
allograft for analyzing the secondary endpoints. The sample
size calculation was performed using NCSS-PASS 2000. Sam-
ple size was estimated based on exact binomial probabilities.
No power analysis for secondary endpoints was done.
All analyses were conducted using SAS 9.4 (SAS Institute,
Cary NC). Data are presented as mean ± SD for continuous
variables and as an absolute number (%) for categorical data.
Baseline characteristics were compared using Student t test
and Fischer exact test due to the small sample size in the
EDC group.
Primary Endpoint
A 1-sided, exact binomial hypothesis test with a target sig-
nificance level α = 0.05 and a target power 1 − β = 0.80 was
used for analysis of the primary endpoint. The primary anal-
ysis was based on the ITTanalysis set. However, a sensitivity
analysis was performed on the per-protocol analysis set to
assess the robustness of the results.
Secondary Endpoints
OS was calculated from the date of transplantation to the
date of death due to any cause. Surviving patients, or patients
lost to follow-up, were classified as censored cases on the
latest date they were confirmed to be alive. Overall organ
allograft survival was calculated from the date of trans-
plantation to the date of last contact when a patient fin-
ished the trial; all patients who died during the trial were
considered as an event regarding organ survival. Organ al-
lografts that survived until study end or organs of patients
lost to follow-up were classified as censored cases on the
latest date a patient was confirmed to be alive.
Differences in time-to-event data between the EDC and the
standard organ group were analyzed using the method of
Kaplan-Meier and the log-rank tests. Survival rates at 3 and
12 months were estimated according to the Kaplan-Meier
product-limit survival estimates. Because of the small sample
size in the EDC group, no multivariable Cox regression
models were calculated.
Time in hospital and number of adverse events (AEs) were
compared using the nonparametric Wilcoxon-Mann-WhitneyCopyright © 2018 Wolters KluwerU test. Proportions were compared using Fishers exact
test. All secondary endpoints were analyzed in a purely
exploratory manner.RESULTS
Patient Recruitment
A total of 79 patients were included from 12 German cen-
ters in the control and EDC groups. The control group was
completed inMarch 2013, with only inclusion of patients re-
ceiving an EDC organ allowed thereafter. However, Germany
experienced a sharp reduction in total organ donor numbers
during this period, requiring a recalculation of the sample size.
As such, only 18 patients were included in the EDC group un-
til the end of the inclusion period inDecember 2014. Although
there were no premature patient withdrawals in the EDC
group, the control group recorded 3 (4%) patients withdraw-
ing their consent, 6 (9%)patients lost to follow-up, and2 (3%)
patient deaths (Figure 1). In the EDC group, inclusion was re-
lated to donor age of 50 years or older in most cases (17 cases,
94%; age range, 50-58 years), with only 1 organ allocated as
EDC due to BMI greater than 30 kg/m2 (1 case [6%]; BMI,
33; age, 35 years). One patient in each group received PTA,
whereas all other patients received SPK.
Recipient and Donor Characteristics
A summary of recipient demographic data is given in
Table 1. There were no statistically significant differences
between both groups. Notably, the following trends were
noted in the EDC group when compared with the standard
group: patients were older (47.7 years vs 43.7 years), suffered
longer from diabetes (32.3 years vs 28.3 years) and required
dialysis for a slightly longer period (3.2 years vs 2.8 years).
Time on the waitlist was slightly shorter for EDC group
patients (18.7 months vs 20.5 months). Almost all patients
(87%) received the recommended immunosuppressive treat-
ment consisting of tacrolimus, mycophenolic acid/mycophenolate
mofetil, and steroids. In total, 4 patients in the EDC group
and 6 patients in the standard group were switched to either
cyclosporine or everolimus (1 in each group) during the study.
Donor demographics are presented in Table 2. Per defini-
tion, EDC donors were substantially older (51.4 years) than
standard group donors (31.7 years). Notably, there was no
difference in BMI between the EDC and the standard groups
(23.3 kg/m2 vs 24.0 kg/m2, respectively) because only 1 donor
was allocated as an extended organ for having a BMI greater
than 30 kg/m2. More female donors were found in the EDC
group when compared with the standard group (78% vs
48%, respectively); no gender-specific outcome was detected
in a subgroup analysis. The main cause of death for EDC
donors was cerebral hemorrhage (89% vs 41% in the stan-
dard group), but none of the EDC donors died from trau-
matic injury (0% vs 34% in the standard group). There
tended to be a higher prevalence of hypertension in EDC
donors (28% vs 12% in the standard group). No substan-
tial difference was observed in the duration of ICU stay
(4.2 days vs 6.9 days), requirement of catecholamine treat-
ment (72% vs 84%), or CIT (9.0 hours vs 10.2 hours) in
the EDC group versus the standard group, respectively.
More donors in the EDC group required insulin before
procurement, when compared with the standard group






(n = 61) P
Male/female 12 (67)/6 (33) 41 (67)/20 (33) 0.965
Age, y 47.7 ± 8 43.7 ± 9 0.085
Body weight, kg 76.9 ± 15 73.5 ± 12 0.316
Time of diabetes, y 32.3 ± 9 28.3 ± 9 0.103
Daily dose of insulin, IU 33 ± 21 33 ± 19 0.940
Medical history
Nephropathy 17 (94) 61 (100) 0.228
Retinopathy 14 (78) 47 (77) 1.000
Neuropathy 12 (67) 34 (56) 0.587
Coronary heart disease 5 (28) 15 (25) 0.766
Peripheral arterial disease 2 (12) 11 (18) 0.722
Chronic dialysis 16 (89) 55 (90) 0.875
Hemodialysis/CAPD 13 (81)/3 (19) 46 (84)/9 (16) 1.000
Time on dialysis, y 3.2 ± 3 2.8 ± 2 0.555
Waiting time for
transplantation, mo
18.7 ± 13 20.5 ± 16 0.895
Data presented as mean ± SD or absolute number (%).
CAPD, continuous ambulatory peritoneal dialysis.
FIGURE 1. Patient disposition.
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The primary endpoint was analyzed as a combined end-
point of graft survival and function at 3 months, defined as
insulin-free graft survival for the EDC group (graft in situ
with detectable c-peptide and no requirement of insulin appli-
cation to the recipient). The primary endpoint was met in
83% of the patients receiving EDC organs (90%CI, 0.62-0.95).
Thus, the minimal accepted organ survival rate of 60%
was not within the CI and reached statistical significance
(P = 0.043). Insulin-free graft survival at 3 months in the
standard group was analyzed to compare outcome data.
The standard organs showed an insulin-free graft survival
rate of 67% at 3 months (90% CI, 0.56-0.77) (P = 0.154).
Graft survival comparison between both groups showed
no significance (P = 0.245) (Figure 2). Notably, 2 patients
in the EDC group had a longer CIT than the advocated
12 hours (12.5 and 13.3 hours, respectively); 1 patient in the
standard group showed a positive crossmatch, and 2 patients
in the standard group were sensitized with a high antibody ti-
ter greater than 60%. After exclusion of these patients from
the analysis (per-protocol analysis), both groups achieved an
insulin-free graft survival of 81% at 3 months.
Secondary Outcome Measures
Pancreas graft survival (detectable c-peptide, recipients
might require insulin treatment) and kidney allograft sur-
vival, as well as overall patient survival throughout the
follow-up period of 1 year, were analyzed as secondary end-
points and presented as Kaplan-Meier curves in Figure 3A-C.
Organ loss of the transplanted pancreas occurred in
3 patients in the EDC group and in 10 patients in the stan-
dard group. This accounts to a probability of pancreas sur-
vival of 100% and 83.3% after 3 and 12 months in the
EDC group versus 94.8% and 83.5% in the standard group,Copyright © 2018 Wolters Kluwer Hrespectively. Reasons for pancreatectomy included pancre-
atitis (n = 5), primary nonfunction (n = 1), thrombosis (n = 3),
partial resection due to thrombosis at month 12 (n = 1),
hyperacute rejection (n = 1), and patient deaths (n = 2 in
standard group). The probability of kidney survival was
100% and 94.4% in the EDC group after 3 and 12 months
versus 94.8% and 94.4% in the standard group, respec-
tively. Notably, 1 patient in the standard group underwent
pancreas retransplantation and 1 in the EDC underwent






(n = 61) P
Male/female 4 (22)/14 (78) 32 (52)/29 (48) 0.031
Age, y 51.4 ± 5 31.7 ± 12 <0.001
BMI, kg/m2 23.3 ± 4 24.0 ± 3 0.319
Days in ICU 4.2 ± 3 6.9 ± 12 0.358
History of hypertensiona 5 (28) 7 (12) 0.059
Requirement of vasoactive drugs 13 (72) 51 (84) 0.313
Requirement of insulin 8 (44) 12 (20) 0.061
Reason of death
Trauma 0 (0) 21 (34.4) 0.002
Apoplexy 1 (5.6) 2 (3.3) 0.545
Cerebral hemorrhage 16 (88.8) 25 (41) <0.001
Other 1 (5.6) 13 (21.3) 0.170
CIT, h 9.0 ± 3 10.2 ± 3 0.128
Data presented as mean ± SD or absolute number (%).
a History of hypertension was unknown for 29 (48%) of standard donors and 9 (50%) of
extended donors.
FIGURE 2. Insulin-free pancreas graft survival at 3months (function-
ing pancreas allografts with detectable c-peptide and no requirement
of insulin treatment to the recipient).
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deaths in the standard group due to multiorgan failure and
sepsis. Both patients died in the early phase of the study, lead-
ing to an OS of 100% after 3 and 12 months in the EDC
group and 96.6% in the standard group.
Assessment of transplanted pancreas function was achieved
by measuring fasting blood glucose, hemoglobin A1c, and
C-peptide levels during follow-up visits (Figure 4A-C). Values
in both groups were equally distributed, indicating a similar
function in both groups. Serum creatinine was used to evaluate
transplanted kidney function (Figure 4D), and no significant
difference was noted.
Safety analyses
Morbidity and mortality data are presented in Table 3.
Patients transplanted with an EDC organ tended to have
a longermedian time inhospital after transplantation (36daysvs
26 days in the standard group). In-hospital morbidity did not
differ between the groups. Classification of postoperative
complications graded according to the Clavien-Dindo clas-
sification12 revealed a higher need for intervention with
general anesthesia (grade IIIb) in the EDC group (44% vs
20% in the standard group), whereas there were more
life-threatening complications (10%) and 2 deaths in the
standard group. Pancreatitis or bleeding/hematoma were
the most common reasons for surgical reintervention. The
number of AEs per patient was slightly higher in the EDC
group (7.0 ± 2.68 vs 5.5 ± 2.47 in the standard group),
whereas life-threatening AEs occurred exclusively in the
standard group (11 events). Biopsy-proven rejection episodes
occurred in 11% of the EDC patients and in 16% of the
standard group patients.
DISCUSSION
Results from this first prospective multicenter study evalu-
ating the outcome of extended criteria pancreas transplanta-
tion indicate excellent outcomes, especially for older donors.
In our trial, 1-year graft survival after pancreas transplan-
tation using primarily donors older than 50 years achieved
allograft survival of 83.3%, which was equal to the ratesCopyright © 2018 Wolters Kluwerattained using standard criteria (83.5%) with the donor
age averaging 31.7 years. Other groups have retrospec-
tively looked at outcomes after pancreas transplantation
using older donors and reported 1-year graft survival rang-
ing from 69% to 81.2%7,13,14; notably, however, the donor
age in these analyses was held to a “lower bar,” where age
limit did not exceed 45 years. The prospective conduct of
our trial, combined with further extension of the age limit
20 years beyond standard donors, paves the way for trans-
planting more patients on the growing transplant waitlists.
Key elements we incorporated for successful extension of
donor limits included local organ procurement to mini-
mize ischemia times and the option to assess organ quality
by the local transplant team.
The preprocurement pancreas suitability score consists of
different donor factors and was introduced in 2008 in the
ET area for the assessment of pancreas organ quality,15 with
a critical cutoff score of 17. In our trial, the EDC group
organs presented, in fact, with a higher (ie, worse) score
than standard organs (17.5 ± 2 vs 16.0 ± 3, respectively).
Although donor age is included in the preprocurement
pancreas suitability score, there are several other factors
also associated with a worse outcome, such as nontrauma
death, high BMI, and long CIT. In EXPAND, EDC donors
were 20 years older than the standard donors (51.4 years vs
31.7 years), but notably also died primarily from cerebrovas-
cular insult. This is an interesting point because Axelrod
et al.16 showed that a cerebrovascular cause of death is a pre-
dictor of graft failure when implementing a donor risk index
for pancreas transplantation. Other retrospective studies
also found that “nontrauma” death17 is associated with a
higher rate of technical failure, along with a BMI greater
than 30 kg/m2 and CIT longer than 12 hours.18 Although BMI
and CITwere below these critical cutoff points in both groups
in our trial, age and reason for death would clearly have pre-
dicted a worse outcome for the EDC organs. Furthermore, Health, Inc. All rights reserved.
FIGURE 3. Survival data. A, Pancreas graft survival (viable pancreas allografts with detectable c-peptide, recipient might require insulin treat-
ment). B, Kidney graft survival, C, OS.
© 2018 Wolters Kluwer Proneth et al 1335adding to the expectation of poorer outcomes in the EDC
group, EDC organs are generally transplanted to older recip-
ients suffering longer from diabetes and having spent more
time on dialysis. In our trial, recipients had been on dialysis
for 3.2 (EDC) versus 2.8 (standard) years. Despite these
higher risk factors, our study did not reveal disadvantagesCopyright © 2018 Wolters Kluwer Hfor EDC recipients. In fact, the standard group patients expe-
rienced 8 life-threatening events during the early posttrans-
plant phase, but there were no such events in the EDC
group. Mortality was higher in the standard group with
2 patient deaths and no deaths in the EDC group. Data
revealed only a slightly longer hospitalization time forealth, Inc. All rights reserved.
FIGURE 4. Organ function. A, Fasting blood glucose. B, HbA1c. C, C-peptide. D, Serum creatinine. HbA1c, hemoglobin A1c.
1336 Transplantation ■ August 2018 ■ Volume 102 ■ Number 8 www.transplantjournal.comEDC patients, and overall in-hospital morbidity showed
also only a slight increase of AEs in EDC patients. We con-
clude that the EDC donor organs selected in our trial pro-
duced 1-year results in recipients that were as good as standard
organ recipients.
Within EXPAND, acceptance of an organ in terms of a
high BMI as an extended criterionwas an option. Despite this
option, only 1 organ from a donor with a BMI greater than
30 kg/m2 was used as an EDC organ, resulting in no real dif-
ference in BMI values (23.3 vs 24.0) between the EDC and
standard groups. Therefore, unfortunately, our study can
only address the issue of using older donors and does not pro-
vide insight into whether donor BMI can be extended. In
terms of accepting a marginal organ, BMI is crucial to most
transplant surgeons for fear of a higher rate of pancreatitis
and graft failure. Notably, organs from obese donors may
be more successful for islet isolation19 and probably should
primarily be allocated for islet cell transplantation.20,21
Whether they will be suitable for pancreas transplantation re-
mains to be elucidated.
In the experience of our participating surgeons, and con-
sistent with our results, their discretion regarding evalua-
tion of the macroscopic organ quality appears to be a major
factor. This general observation leads to the recommendation
that an important factor contributing to good outcomes when
using older organs is the selection of dedicated and experiencedCopyright © 2018 Wolters Kluwercenters. Notably, transplantation of the EDC organs was only
performed in 4 high-volume centers of the 12 participating
centers. However, this means that a substantial portion of
the standard group patients were transplanted in low-volume
centers, leaving open the possibility of a slight bias toward
inferior outcomes in the control group.22
Considering our outcome data, there is a clear potential
impact for patients on the waitlist. In an analysis of the
OPTN registries, Gruessner et al.3 noted 5-year graft survival
rates of 61% from donors older than 45 years, as compared
with 72% from standard donors with a 5-year patient sur-
vival of 81% and 84.5%, respectively. Importantly, patients
remaining on the waitlist only achieved a 5-year survival rate
of 45%. This underscores the importance of early transplan-
tation and the critical need for more organs to improve out-
comes of otherwise long waitlisted patients. We managed to
reduce the time on the waitlist from 20.5 to 18.7 months
when patients were transplanted with an EDC organ. With
further experience in the use of EDC organs, waiting times
could be reduced even further. For sensitized patients or pa-
tients with blood group type complications, the typically lon-
ger waiting times could be reduced substantially by using
older EDC organs, even if long-term organ function should
prove to be shorter for older organs. Notably, long-term out-
comeswere not evaluated in our trial, so this aspect still needs
to be tested in further studies. Health, Inc. All rights reserved.
TABLE 3.




(n = 61) P
Time in hospital:
median (IQR), da
36 (18-51) 26 (19-37) 0.409 (WMW)
Overall mortality 0 (0) 2 (3) 0.433 (LR)
In-hospital morbidity 13 (72) 43 (70) 1.00 (FT)
Classification Clavien-Dindo
None 5 (28) 18 (30) 0.644 (WMW)b
I 1 (6) 14 (23)
II 4 (22) 7 (11)
IIIa 0 (0) 2 (3)
IIIb 8 (44) 12 (20)
IVa 0 (0) 6 (10)
IVb 0 0
V 0 (0) 2 (3)
No. AEs 126 336
AE number per patient 7.00 ± 2.68 5.51 ± 2.47 0.052 (WMW)
No. severe AE 21 (17) 40 (12) 0.216 (FT)
No. life-threatening AE 0 (0) 11 (3) <0.001 (FT)
Biopsy-proven
acute rejection
2 (11) 10 (16) 0.724 (FT)
Data presented as median (IQR), mean ± SD, or absolute number (%).
a 2 (3%) patients died in hospital and 2 (3%) patients withdraw from study in the standard group.
b P value indicates if one of the ordinal distributions is stochastically greater than the other.
WMW, Wilcoxon-Mann-Whitney test; LR, log-rank test; FT, Fischer exact test.
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In conclusion, the EXPAND study is the first prospective
multicenter trial comparing and evaluating the outcomes of
standard criteria in deceased donor pancreas organs to ex-
tended criteria organs. Our results show excellent outcomes
after transplantation with organs from donors older than
50 years, when a careful selection is made at the discretion
of the transplant surgeon. This finding also strengthens the
necessity for evaluation and harvesting of organs by the (lo-
cal) transplantation teamswith regional allocation.More im-
portantly, EDC organs did not pose a higher risk for early
graft loss or morbidity, and no overall contraindicative disad-
vantages were observed over the first year posttransplanta-
tion. This clinical trial substantiates the full implementation
of older donors in the pancreas organ allocation process,
leading to a potentially significant expansion of the available
donor pool.
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